Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial

{ 'indexed': {'date-parts': [[2024, 2, 7]], 'date-time': '2024-02-07T08:36:27Z', 'timestamp': 1707294987655}, 'reference-count': 27, 'publisher': 'Springer Science and Business Media LLC', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2021, 7, 28]], 'date-time': '2021-07-28T00:00:00Z', 'timestamp': 1627430400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}, { 'start': { 'date-parts': [[2021, 7, 28]], 'date-time': '2021-07-28T00:00:00Z', 'timestamp': 1627430400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'DOI': '10.13039/501100013302', 'name': 'King Abdullah International Medical Research Center', 'doi-asserted-by': 'publisher', 'award': ['RC20/174/R']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 12]]}, 'DOI': '10.1007/s40121-021-00496-6', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 10]], 'date-time': '2021-08-10T17:07:26Z', 'timestamp': 1628615246000}, 'page': '2291-2307', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 9, 'title': 'Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe ' 'COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial', 'prefix': '10.1007', 'volume': '10', 'clinical-trial-number': [ { 'clinical-trial-number': 'nct04392973', 'registry': '10.18810/clinical-trials-gov'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-2971-5141', 'authenticated-orcid': False, 'given': 'Mohammad', 'family': 'Bosaeed', 'sequence': 'first', 'affiliation': []}, {'given': 'Ebrahim', 'family': 'Mahmoud', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmad', 'family': 'Alharbi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hadeel', 'family': 'Altayib', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hawra', 'family': 'Albayat', 'sequence': 'additional', 'affiliation': []}, {'given': 'Faisal', 'family': 'Alharbi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Khalid', 'family': 'Ghalilah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdulmajid', 'family': 'Al Arfaj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jumana', 'family': 'AlJishi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdullatif', 'family': 'Alarfaj', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hajar', 'family': 'Alqahtani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Badriah M.', 'family': 'Almutairi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Manar', 'family': 'Almaghaslah', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nawaf M.', 'family': 'Alyahya', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdullah', 'family': 'Bawazir', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saud', 'family': 'AlEisa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdulrahman', 'family': 'Alsaedy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abderrezak', 'family': 'Bouchama', 'sequence': 'additional', 'affiliation': []}, {'given': 'Malak', 'family': 'Alharbi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Majid', 'family': 'AlShamrani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sameera', 'family': 'Al Johani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Majed', 'family': 'Aljeraisy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohammed', 'family': 'Alzahrani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Abdulhakeem O.', 'family': 'Althaqafi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hassan', 'family': 'Almarhabi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Athari', 'family': 'Alotaibi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nasser', 'family': 'Alqahtani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yaseen M.', 'family': 'Arabi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Omar S.', 'family': 'Aldibasi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ahmad', 'family': 'Alaskar', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 7, 28]]}, 'reference': [ { 'key': '496_CR1', 'unstructured': 'World Health Organization. Coronavirus Disease (COVID-19) Situation ' 'Report. ' 'https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. ' 'Accessed 15 2021. (Published 15 April 2021).'}, { 'issue': '13', 'key': '496_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'volume': '323', 'author': 'Z Wu', 'year': '2020', 'unstructured': 'Wu Z, McGoogan JM. Characteristics of and important lessons from the ' 'coronavirus disease 2019 (COVID-19) outbreak in China: summary of a ' 'Report of 72 314 Cases From the Chinese Center for Disease Control and ' 'Prevention. JAMA. 2020;323 (13):1239.', 'journal-title': 'JAMA'}, { 'issue': '12', 'key': '496_CR3', 'doi-asserted-by': 'publisher', 'first-page': 'e2029058', 'DOI': '10.1001/jamanetworkopen.2020.29058', 'volume': '3', 'author': 'N Rosenthal', 'year': '2020', 'unstructured': 'Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated ' 'with in-hospital mortality in a US national sample of patients with ' 'COVID-19. JAMA Netw Open. 2020;3 (12):e2029058.', 'journal-title': 'JAMA Netw Open.'}, { 'issue': '11', 'key': '496_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1436', 'DOI': '10.1001/jamainternmed.2020.3596', 'volume': '180', 'author': 'S Gupta', 'year': '2020', 'unstructured': 'Gupta S, Hayek SS, Wang W, et al. Factors associated with death in ' 'critically ill patients with coronavirus disease 2019 in the US. JAMA ' 'Intern Med. 2020;180 (11):1436.', 'journal-title': 'JAMA Intern Med'}, { 'issue': '8', 'key': '496_CR5', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'volume': '384', 'author': 'P Horby', 'year': '2021', 'unstructured': 'Horby P, Lim WS, RECOVERY Collaborative Group, et al. Dexamethasone in ' 'hospitalized patients with Covid-19. N Engl J Med. 2021;384 (8):693–704.', 'journal-title': 'N Engl J Med.'}, { 'issue': '16', 'key': '496_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1491', 'DOI': '10.1056/NEJMoa2100433', 'volume': '384', 'author': 'AC Gordon', 'year': '2021', 'unstructured': 'Gordon AC, Mouncey PR, REMAP-CAP Investigators, et al. Interleukin-6 ' 'receptor antagonists in critically ill patients with Covid-19. N Engl J ' 'Med. 2021;384 (16):1491–502.', 'journal-title': 'N Engl J Med.'}, { 'key': '496_CR7', 'doi-asserted-by': 'publisher', 'first-page': '85', 'DOI': '10.1016/j.antiviral.2018.03.003', 'volume': '153', 'author': 'L Delang', 'year': '2018', 'unstructured': 'Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential ' 'countermeasure against neglected and emerging RNA viruses. Antivir Res. ' '2018;153:85–94.', 'journal-title': 'Antivir Res'}, { 'issue': '7', 'key': '496_CR8', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'volume': '93', 'author': 'Y Furuta', 'year': '2017', 'unstructured': 'Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum ' 'inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. ' '2017;93 (7):449–63.', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '496_CR9', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.03.17.20037432', 'author': 'C Chen', 'year': '2020', 'unstructured': 'Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for ' 'COVID-19: a randomized clinical trial [Internet]. Infect Dis (except ' 'HIV/AIDS). 2020. https://doi.org/10.1101/2020.03.17.20037432.', 'journal-title': 'Infect Dis (except HIV/AIDS)'}, { 'key': '496_CR10', 'first-page': '62', 'volume': '103', 'author': 'ZF Udwadia', 'year': '2021', 'unstructured': 'Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of ' 'favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in ' 'mild-to-moderate COVID-19: A randomized, comparative, open-label, ' 'multicenter, phase 3 clinical trial. Int J Infect Dis IJID Off Publ Int ' 'Soc Infect Dis. 2021;103:62–71.', 'journal-title': 'Int J Infect Dis IJID Off Publ Int Soc Infect Dis'}, { 'issue': '1', 'key': '496_CR11', 'doi-asserted-by': 'publisher', 'first-page': '904', 'DOI': '10.1186/s13063-020-04825-x', 'volume': '21', 'author': 'M Bosaeed', 'year': '2020', 'unstructured': 'Bosaeed M, Mahmoud E, Hussein M, et al. A Trial of Favipiravir and ' 'Hydroxychloroquine combination in Adults Hospitalized with moderate and ' 'severe Covid-19: a structured summary of a study protocol for a ' 'randomised controlled trial. Trials. 2020;21 (1):904.', 'journal-title': 'Trials'}, { 'issue': '6', 'key': '496_CR12', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1056/NEJMoa2023184', 'volume': '384', 'author': 'H Pan', 'year': '2021', 'unstructured': 'Pan H, Peto R, WHO Solidarity Trial Consortium, et al. Repurposed ' 'antiviral drugs for Covid-19—interim WHO solidarity trial results. N ' 'Engl J Med. 2021;384 (6):497–511.', 'journal-title': 'N Engl J Med.'}, { 'issue': '15', 'key': '496_CR13', 'doi-asserted-by': 'publisher', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'volume': '71', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection ' 'of optimized dosing design of hydroxychloroquine for the treatment of ' 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin ' 'Infect Dis. 2020;71 (15):732–9.', 'journal-title': 'Clin Infect Dis'}, { 'issue': '19', 'key': '496_CR14', 'doi-asserted-by': 'publisher', 'first-page': '1813', 'DOI': '10.1056/NEJMoa2007764', 'volume': '383', 'author': 'JH Beigel', 'year': '2020', 'unstructured': 'Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of ' 'Covid-19—final report. N Engl J Med. 2020;383 (19):1813–26.', 'journal-title': 'N Engl J Med'}, { 'issue': '11', 'key': '496_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1048', 'DOI': '10.1001/jama.2020.16349', 'volume': '324', 'author': 'CD Spinner', 'year': '2020', 'unstructured': 'Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs ' 'standard care on clinical status at 11 days in patients with moderate ' 'COVID-19: a randomized clinical trial. JAMA. 2020;324 (11):1048.', 'journal-title': 'JAMA'}, { 'issue': '10236', 'key': '496_CR16', 'doi-asserted-by': 'publisher', 'first-page': '1569', 'DOI': '10.1016/S0140-6736(20)31022-9', 'volume': '395', 'author': 'Y Wang', 'year': '2020', 'unstructured': 'Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: ' 'a randomised, double-blind, placebo-controlled, multicentre trial. ' 'Lancet Lond Engl. 2020;395 (10236):1569–78.', 'journal-title': 'Lancet Lond Engl'}, { 'issue': '6', 'key': '496_CR17', 'doi-asserted-by': 'publisher', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'volume': '383', 'author': 'DR Boulware', 'year': '2020', 'unstructured': 'Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of ' 'Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J ' 'Med. 2020;383 (6):517–25.', 'journal-title': 'N Engl J Med'}, { 'issue': '24', 'key': '496_CR18', 'doi-asserted-by': 'publisher', 'first-page': '2493', 'DOI': '10.1001/jama.2020.8630', 'volume': '323', 'author': 'ES Rosenberg', 'year': '2020', 'unstructured': 'Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with ' 'hydroxychloroquine or azithromycin with in-hospital mortality in ' 'patients with COVID-19 in New York State. JAMA. 2020;323 (24):2493–502.', 'journal-title': 'JAMA'}, { 'issue': '1', 'key': '496_CR19', 'doi-asserted-by': 'publisher', 'first-page': '20', 'DOI': '10.1056/NEJMoa2030340', 'volume': '384', 'author': 'C Salama', 'year': '2021', 'unstructured': 'Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with ' 'Covid-19 pneumonia. N Engl J Med. 2021;384 (1):20–30.', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '496_CR20', 'doi-asserted-by': 'publisher', 'first-page': '530', 'DOI': '10.1111/fcp.12586', 'volume': '34', 'author': 'F Lemaitre', 'year': '2020', 'unstructured': 'Lemaitre F, Solas C, Grégoire M, et al. Potential drug–drug interactions ' 'associated with drugs currently proposed for COVID-19 treatment in ' 'patients receiving other treatments. Fundam Clin Pharmacol. 2020;34 ' '(5):530–47.', 'journal-title': 'Fundam Clin Pharmacol'}, { 'issue': '3', 'key': '496_CR21', 'doi-asserted-by': 'publisher', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'volume': '30', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively ' 'inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. ' 'Cell Res. 2020;30 (3):269–71.', 'journal-title': 'Cell Res'}, { 'key': '496_CR22', 'first-page': 'CD013587', 'volume': '2', 'author': 'B Singh', 'year': '2021', 'unstructured': 'Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or ' 'hydroxychloroquine for prevention and treatment of COVID-19. Cochrane ' 'Database Syst Rev. 2021;2:CD013587.', 'journal-title': 'Cochrane Database Syst Rev.'}, { 'issue': '3', 'key': '496_CR23', 'doi-asserted-by': 'publisher', 'first-page': '949', 'DOI': '10.1007/s00705-021-04956-9', 'volume': '166', 'author': 'HM Dabbous', 'year': '2021', 'unstructured': 'Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir ' 'in COVID-19 treatment: a multi-center randomized study. Arch Virol. ' '2021;166 (3):949–54.', 'journal-title': 'Arch Virol'}, { 'key': '496_CR24', 'first-page': '1176', 'volume': '2', 'author': 'AA Ivashchenko', 'year': '2020', 'unstructured': 'Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment ' 'of patients with moderate COVID-19: interim results of a Phase II/III ' 'multicenter randomized clinical trial. Clin Infect Dis Off Publ Infect ' 'Dis Soc Am. 2020;2:1176.', 'journal-title': 'Clin Infect Dis Off Publ Infect Dis Soc Am'}, { 'key': '496_CR25', 'doi-asserted-by': 'publisher', 'first-page': '107522', 'DOI': '10.1016/j.intimp.2021.107522', 'volume': '95', 'author': 'M Solaymani-Dodaran', 'year': '2021', 'unstructured': 'Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of ' 'Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int ' 'Immunopharmacol. 2021;95:107522.', 'journal-title': 'Int Immunopharmacol.'}, { 'issue': '21', 'key': '496_CR26', 'doi-asserted-by': 'publisher', 'first-page': '2041', 'DOI': '10.1056/NEJMoa2019014', 'volume': '383', 'author': 'AB Cavalcanti', 'year': '2020', 'unstructured': 'Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or ' 'without azithromycin in mild-to-moderate Covid-19. N Engl J Med. ' '2020;383 (21):2041–52.', 'journal-title': 'N Engl J Med'}, { 'issue': '12', 'key': '496_CR27', 'doi-asserted-by': 'crossref', 'first-page': 'e01897-20', 'DOI': '10.1128/AAC.01897-20', 'volume': '64', 'author': 'Y Doni', 'year': '2020', 'unstructured': 'Doni Y, Hibino M, Hase R, et al. A prospective, randomized, open-label ' 'trial of early versus late favipiravir therapy in hospitalized patients ' 'with COVID-19. Antimicrob Agents Chemother. 2020;64 (12):e01897-20.', 'journal-title': 'Antimicrob Agents Chemother.'}], 'container-title': 'Infectious Diseases and Therapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-021-00496-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s40121-021-00496-6/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s40121-021-00496-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 1, 7]], 'date-time': '2023-01-07T02:05:55Z', 'timestamp': 1673057155000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s40121-021-00496-6'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 28]]}, 'references-count': 27, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['496'], 'URL': 'http://dx.doi.org/10.1007/s40121-021-00496-6', 'relation': {}, 'ISSN': ['2193-8229', '2193-6382'], 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'container-title-short': 'Infect Dis Ther', 'published': {'date-parts': [[2021, 7, 28]]}, 'assertion': [ { 'value': '3 June 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '1 July 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '28 July 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}]}